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(Figure 1) [1]. The aureolic acids are neoplastic antibiot-Aureolic Acids: Similar Antibiotics
ics that act against gram-positive bacteria and also stopwith Different Biosynthetic the proliferation of tumor cells [2]. In the presence of
Gene Clusters Mg2, these compounds inhibit replication and tran-
scription processes by interacting with G-C-rich regions
in the minor groove of DNA [3]. Mithramycin (plicamycin),
the only clinically used aureolic acid, is currently in lim-
In this issue of Chemistry & Biology, Me´ndez and col- ited use for the treatment of some testicular cancers
leagues describe the sequence and organization of [4], Paget’s Bone Disease [5], and the treatment of hy-
the chromomycin gene cluster [20]. Unexpectedly, the percalciuria that results from certain tumors [6].
arrangement is starkly different from the mithramycin The biosynthetic pathway of mithramycin, a represen-
biosynthetic cluster, despite similarity in the individual tative member of the aureolic acids, was ultimately eluci-
genes and the near identical structures of the two dated by genetic studies of the producing organism,
antibiotic aureolic acids. Streptomyces argillaceus [1]. Sequencing of the mithra-
mycin biosynthetic gene cluster indicated that ten ace-
tate units are converted into a 20 carbon chain by theThe aureolic acids, chromomycin A3, mithramycin, oli-
combined action of an acyl carrier protein, a ketosyn-vomycin, UCH9, and durhamycin A, are a family of aro-
matic polyketides that share an identical tricyclic core thase, and a chain length factor in a mechanism that is
Previews
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Figure 1. Structures of the Chromomycin
and Mithramycin Products
Black, mithramycin; red, chromomycin.
typical of aromatic (type II) polyketide biosynthesis [7]. distantly related organisms. These observations sug-
A ketoreductase, aromatase, and two cyclases convert gest that horizontal gene transfer of secondary meta-
this linear chain to a tetracyclic intermediate that is sub- bolic pathways occurs among distantly related species
sequently hydroxylated, methylated, and glycosylated [15, 16]. In other words, the biosynthetic apparatus for
[1]. In the penultimate step, the unsaturated carbonyl of an antibiotic (or other metabolite) can be transferred to
one of the rings is subjected to a Bayer-Villager oxidation another organism, presumably conferring some selec-
that converts the 6-membered ring to a 7-membered tive advantage for the recipient species. However, if
lactone, which then hydrolyzes to generate the final tri- either mithramycin or chromomycin was acquired by
cyclic ring structure [8]. In the final step, one of the keto horizontal gene transfer, the differences in the two clus-
groups of the newly opened fourth ring is reduced to a ters suggest that substantial gene reorganization must
hydroxyl group to yield mithramycin [9]. have taken place. The driving force for such reorganiza-
The aglycone of mithramycin is identical to chro- tion remains unclear.
momycin, with the only structural differences between Aside from any evolutionary implications, this study
the two compounds residing in the sugars that decorate reveals that a specific arrangement of genes does not
the polyketide. Specifically, the saccharides of chro- necessarily affect the resulting protein machinery and
momycin are derivatized with acetyl groups, a methoxy production of the antibiotic. This information is impor-
group, and the stereochemistry of saccharide E is al- tant for the emerging field of “combinatorial biosynthe-
tered (Figure 1). Subtle structural differences can modu- sis,” in which biosynthetic pathways are modified by
late the biological activity of an antibiotic; in this case, deleting, adding, or replacing genes to produce a modi-
the acetyl groups appear to enhance the binding of fied metabolite [17–19]. Modification of a biosynthetic
chromomycin to short DNA sequences in vitro [10]. How- gene cluster may lead to the development of analogs
ever, despite the improved DNA binding relative to that retain biological activity while exhibiting mitigated
mithramycin, the clinical use of chromomycin (also side effects. The authors used combinatorial biosynthe-
known as toyomycin or aburamycin) is limited due to sis in this study and in previously reported work to inves-
toxic side effects such as necrosis and renal toxicity [11].
tigate the role of the aliphatic side chain in aureolic acid
Here, Me´ndez and coworkers report the sequence of
activity (Figure 1). By deleting a reductase that acts on
the chromomycin gene cluster (Streptomyces griseus),
this side chain, mithramycin and chromomycin analogsthe second member of the aureolic acid family to be
with modified side chains were produced that exhibitedsequenced. [20] Given the similarity between the chemi-
improved (in the case of mithramycin [9]) or reducedcal structures of mithramycin and chromomycin, it was
(chromomycin) activity with respect to the original anti-expected that the two clusters would be nearly identical.
biotic.However, although there is high homology between indi-
In the context of combinatorial biosynthesis, a prac-vidual mithramycin and chromomycin genes, the ar-
tice in which gene clusters are genetically altered, itrangement of the genes in the chromomycin cluster is
would be particularly useful to establish whether thereorganized in a substantially different way. For example,
are any rules regarding the organization of clusters. Ain the mithramycin cluster, the genes that encode the
preliminary analysis of the mithramycin and chro-proteins for polyketide biosynthesis are clustered to-
momycin clusters suggests that a dramatic rearrange-gether. In the chromomycin system, the homologs of
ment in the order of the genes still results in successfulthese genes are scattered throughout the cluster and
expression of the aureolic acid antibiotic. As sequencingare interspersed with genes involved in regulation, resis-
efforts of metabolic pathways continue, other examplestance, and sugar biosynthesis.
of rearranged clusters may emerge that will provide fur-Recent studies have shown that similar aromatic poly-
ther insight into how antibiotic biosynthetic gene clus-ketide [12], streptomycin [13], and penicillin [14] gene
clusters or portions of clusters are found in otherwise ters are arranged.
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and ammonia, while using the  carbon of the aminoUnraveling the Pathway
acid to generate N5,N10-methylene-tetrahydrofolate.of Lipoic Acid Biosynthesis Again, all of this takes place with concomitant reduction
of NAD to NADH [1].
The Biosynthesis of Lipoic Acid
Given the importance of the lipoyl group in central me-Lipoic acid is almost universally required for aerobic
tabolism, it should not be surprising that many organ-metabolism. However, the mechanism for its synthesis
isms elaborate more than one pathway to incorporateand incorporation into proteins has remained elusive.
it into those complexes that require it. In the cell, veryA groundbreaking study published in the December
little lipoate exists as the free acid; almost all is tetheredissue of Chemistry & Biology [20] uncovers critical
to the -amino group of a conserved lysine residue onfeatures of the lipoic acid biosynthetic pathway.
lipoyl-accepting domains of target complexes. Pioneer-
ing studies from John Cronan’s laboratory indicate thatLearning about the pyruvate dehydrogenase complex
E. coli maintain at least two pathways for attaching the(PDC) has evolved into a rite of passage for every begin-
lipoyl group to these target lysine residues (Figure 1) [2].ning biochemist. Few have been spared the analogy of
Lipoic acid that the organism obtains from the medium isthe lipoyl group acting as a crane in a construction yard,
first activated by ATP, and then transferred and ap-methodically removing intermediates from one subunit
pended with concomitant release of AMP. In E. coli,of the complex and successively delivering them to the
both steps are catalyzed by a lipoate-protein ligase,active sites of others. Pyruvate and coenzyme A (CoA)
which is designated LplA [3]. LplA also will use octanoicenter the complex, while CO2 and acetyl-CoA exit. In the
acid as a substrate, albeit with reduced efficiency [4].process, NAD is reduced to NADH. Other very worthy
Alternatively, the lipoyl group can be synthesized endog-cofactors, such as thiamin diphosphate (TDP) and flavin
enously as an offshoot of fatty acid biosynthesis. Theadenine dinucleotide (FAD), participate in the reaction;
exact details of this pathway have not been completelyhowever, the lipoyl group and its associated subunit
illuminated; however, the major players have been iden-(E2) serve as the core of this gigantic factory. The lipoyl
tified and are currently being characterized. LipB is agroup makes repeat performances in several other multi-
lipoyl (octanoyl)-transferase; it can transfer either a lipoylenzyme complexes that are involved in primary and sec-
or octanoyl group from a bacterial type II acyl carrierondary metabolism. These include the -ketoglutarate
protein (ACP) to lipoyl-accepting domains [4, 5]. LipAdehydrogenase complex (KGDC) of the citric acid cycle,
catalyzes sulfur insertion into the octanoyl group, form-the branched-chain 2-oxo acid dehydrogenase complex
ing the lipoyl appendage [6]. Evidence for similar endog-(BCDC), which is important in the metabolism of several
enous pathways in several eukaryotes has also sur-of the branched-chain amino acids, and the glycine
cleavage system (GCS), which degrades glycine to CO2 faced, providing rationale for the previously unexplained
